Outcome of Board Meeting

~ AJOONI BIOTECH LIMITED ‘ Regd. Office: D-118, Industrial Area, Phase VII, Mohali-160055 (Pb.) - '_ Corp Office: H.No 1769, Phase 3B2, Mohali-160059 Ajooni biotech Phone: 0172-5020758-69 Website: www.ajoonibiotech.com E-mail: ajooni.biotech@gmail.com / info@ajoonibiotech.com CIN: L85190PB2010PLC040162 August 14, 2026 National Stock Exchange of India Ltd Exchange Plaza, Plot no. C/1, G Block, Bandra-Kurla Complex, Bandra (E) Mumbai - 400051 Dear Sir / Madam, Subject: Outcome of the Board Meeting held on Friday, August 14, 2026, pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015. SYMBOL: AJOONI Dear Sir/Madam, With reference to the above captioned subject, we wish to inform you that the Board of Directors of the Company at their meeting held on Friday, August 14 2026 at 03.00 p.m concluded at 03.45 p.m. Following transactions were considered and approved: 1. Un-audited Financial Results for the quarter ended June 30, 2026. 2. Limited Review Report from the auditor for the quarter ended June 30, 2026. You are requested to kindly take the same on your record and acknowledge receipt. Thanking You, Yours Truly, For Ajooni Biotech Limited Jasjot Singh Managing Director DIN: 01937631 Works: G.T. Road, Khanna- 141401 (Punjab) INDIA AJOONI BIOTECH LIMITED CIN : L85190PB2010PLC040162 STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2026(In Lakhs) PARTICULARS QUARTER ENDED 30.06.2026 31.03.2026 30.06.2025 ‘;fi:‘:‘ d?::;d l:;':“:’“:i"‘f;d 31.03.2026 30.06.2026, 30.06.2025 1 [income Revenue from operations 6,349.07 6,062.21 3,126.77 6,349.07 3,126.77 18,237.81 Other income 26.89 130.43 64.54 26.89 64.54 24181 [T otal income from operations 6,375.96 6,192.64 3,191.31 6,375.96 3,191.31 18,479.62 11_|Expenses |Cost of Material Consumed 5,454.86 4,915.56 2,564.17 5,454.86 2,564.17 14,805.33 Change In Inventories (39.06) (0.83), (4.18) (39.06) (4.18) (12.54) Employee benefit expenses 137.59 127.78 99.21 137.59 99.21 457.29 Finance costs 48.21 28.95 8.46 48.21 8.46 72.94 Depreciation and amortization expenses 80.27 89.79 24.83 80.27 24.83 220.63 Payment to NSE |Other expenses 628.65 919.36 396.10 628.65 396.10 2,362.14 [Total expenses 6,310.52 6,080.61 3,088.59 6,310.52 3,088.59 17,905.79 111 |Profit/(Loss) before exceptional items and tax 65.44 112.03 102.72 65.44 102.72 573.83 1V [Exceptional items V |Profit/(Loss) before tax 65.44 112.03 102.72 65.44 102.72 573.83 VI [Tax expenses a) Current tax 18.62 28.17 22.50 18.62 22.50 153.01 b) Deferred tax 3.64 1086 208 364 08 137 b) Mat Credit VII [Net Profit/(Loss) for the period/year 43.18 94.72 78.14 43.18 78.14 432.19 V111 |Other comprehensive income (net of tax) & loss: 84.03 - (120.94) Total other comprehensive income 84.03 (120.94) Total comprehensive income for the period/year IX [(VIEHVII 43.18 10.69 - 2 43.18 - 311.10 Paid-up cquity share capital (face value of the / DL X [share shall be indicated) 3,444.87 3,444.87 3aYsT| 44.87 | 344487 3,444.87 C}‘M OHA L X1 |Other equity (excluding revaluation reserve) 5,717.45 5,674.27 5,441.16 5,717.45 5441.16 5.674.27 XI1 [EPS in Rs. (Face Value of Rs.10/- each)* a2 -Basic 0.01 0.05 0.02 0.01 0.02 025 -Diluted 0.01 0.05 0.02 0.01 0.02 0.25 Notes: 1. The above results are as per Regulation 33 of the SEBI (LODR) Regulations, 2015 as amended and have been taken on record by Board of Directors at its meeting held on 12.08.2026 after being reviewed by the Audit Committee. 2. The company is having single segment in accordance with IND AS 108 "operating segments". and therefore segment reporting is not applicable to the Company. 3. Due to re-grouping of schedules, and as per applicability of IND-AS, there has been a difference in the figures as reported earlier. Place : Mohali Date : 14/08/2026 Managing Direcl DIN: 01937631 AJOONI BIOTECH LIMITED CIN : L85190PB2010PLC040162 Statement of Assets and Liabilities For the Year ended on 30th June 2026 in Rs. (Lakhs) PARTICULARS 30TH JUNE 2026 31ST MARCH 2026 LA. SSETS (1) Non - Current Assets a) Property, Plant and Equipnent 2,948.92 2,585.57 b) Capital Work In Progress 0.00 0.00 c) Investment Property d) Goodwill e) Other Intangible Assets 35.94 35.95 f) Intangible Assets Under Deyelopment g) Biological Assets other thar) Bearer Plants h) Financial Assets (1) Investments 233.18 244.75 (2) Trade Receivables (3) Loans (4) Other Financial Assets 1,500.00 1,500.00 i) Deffered Tax Asset (net) 52.94 49.29 j) Other Non Current Asset 273.07 173.30 (2) Current Assets 4,181.02 3,945.51 a) Inventories b) Financial Assets (1) Investments (2) Trade Receivables 1,656.08 1,783.43 (3) Cash & Cash Equivalent 37.36 41.90 (4) Bank Balances other than (iii) above 1,366.60 1,414.92 (5) Loans 69.98 (6) Other Financial Asset ¢) Current Tax Assets (net) 205.77 191.91 d) Other Current Asset TOTAL 12,490.88 12,036.51 11 EQUITY AND LIABILITIES (1) Equity i a)Equity Share Capital 3,444.87 3,444.87 b) Other Equity 5,717.45 5,674.28 (2) Non-Current Liabilities a) Financial Liabilities (1) Borrowings 140.83 154.00 (2) Trade Payables (3) Other Financial Liabiltie} b) Employee Benefit Obligations 30.34 28.65 c) Deferred Tax Liability (net) - d) Other Non Current Liability - (3) Current Liabilities a) Financial Liabilities (1) Borrowings 2,550.27 1,622.28 (2) Trade Payables 560.02 891.41 (3) Other Financial Liabiliti¢s b) Employee Benefit Obligations 1.90 1.69 c) Other Current Liabilities 26.58 66.32 d) Current tax liabilities (Net) 18.62 153.01 TOTAL 12,490.88 12,036.51 Place : Mohali Date : 14.08.2026 DIN: 01937631 SCO 65-B (1st Floor) City Heart, KKhhaarraarr, CShAanSd iNgaagrahr RMooahda,l i-140301 NARINDER KUMAR AND COMPANY Mobile : 98154 50065 CHARTERED ACCOUNTANTS Email : nkgargca@yahoo.co.in _ Limited Review Report 2117 [ MR —— Review Report to Board of Directors of M/s Ajooni Biotech Limited. We have reviewed the accompanying statement of unaudited financial results of M/s Ajooni Biotech Limited having Regd. office at D-118, Industrial Area, Phase-VII, Mohali Punjab- 160055. for the period ended 30th June 2026.(the Statement) attached herewith , being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and disclosure requirements) regulations 2015 (as amended) , Including relevant circulars issued by the Securities and Exchange Board of India (SEBI) from time to Time. This statement is the responsibility of the Company’s Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement. or NARINDER KUMAR AND COMPANY N Chartered Accountants (NARINDER KIIMAR GARG) PARTNER M.NO-080287 Date:-14.08.2026 UDIN:- 26080287YCZIRL9409